Home
Hibercell

Hibercell Market Share Analysis for May 2026

Developing therapies targeting adaptive-stress driven vulnerabilities to combat treatment resistance, cancer relapse, and metastasis.

Industry: N/A

Domainhibercell.com

Year Founded2018

Employees51 - 200

Annual Revenue$2M - $5M

Hibercell

Hibercell (including company regionals)

hibercell.com

See more website traffic and engagement information

Hibercell Revenue up to May 2026 is 2M - 5M

revenue generated by Hibercell top domains

Hibercell top domains revenue over 3 years

Revenue for Hibercell top domains

hibercell.com2M - 5M

See more with Sales Intelligence

Total visits to Hibercell's top domains

Understand Hibercell market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

hibercell.com522

See more with Sales Intelligence

Avg. visit duration in Hibercell's top domains

Analyze Hibercell engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

hibercell.com00:01:06

See more with Sales Intelligence

Avg. pageviews on Hibercell's top domains

See how Hibercell keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

hibercell.com2.36

See more with Sales Intelligence

Hibercell top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Hibercell

These are the website technologies, by industry, used by Hibercell top domains

Widget (5)

Twemoji

Payment & Currencies (3)

PayPal

Content Management System (2)

WordPress

Marketing (2)

Google Marketing Platform

More Technologies

8

See all

News & Signals from Hibercell

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsHibercell Inc received financing of $61M in Series A on Jan 1st '19.He was Co-Founder, President, and CEO of HiberCell, a US based biotechnology company that was launched in 2019 with a USD 61 million Series A. Prior to HiberCell, he held C-Suite positions at biopharma companies including Warp Drive Bio, Inc., Synta Pharmaceuticals, as well as senior Executive positions at Eli Lilly and Company.

NewsHibercell Inc launches QuAD[3] Platform.Under his guidance, HiberCell launched the QuAD[3] (Quantum Artificial Intelligence Drug Discovery and Development) Platform, setting new standards in the field.

NewsHibercell Inc hired Jonathan Lanfear as chief operating officer on Sep 30th '21.HiberCell, a clinical stage biotechnology company developing therapeutics to treat cancer relapse and metastasis, today announced the appointment of Jonathan Lanfear as chief operating officer with a focus on leading and driving HiberCell’s emerging global reach.